Pasar al contenido principal

EFICACIA DE NANOPARTICULAS RECUBIERTAS CON MEMBRANAS CELULARES HIBRIDAS COMO TERAPIA DIRIGIDA FRENTE A LA HETEROGENEIDAD TUMORAL DEL CANCER DE MAMA Y PANCREAS

PID2022-140151OB-C22

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD DE GRANADA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Autologous patient-derived exhausted nano T-cells exploit tumor immune evasion to engage an effective cancer therapy

  • Blaya-Cánovas, José L.
  • Griñán-Lisón, Carmen
  • Blancas, Isabel
  • Marchal, Juan A.
  • Ramírez-Tortosa, César
  • López-Tejada, Araceli
  • Benabdellah, Karim
  • Cortijo-Gutiérrez, Marina
  • Cano-Cortés, M. Victoria
  • Graván, Pablo
  • Navarro-Marchal, Saúl A.
  • Gómez-Morales, Jaime
  • Delgado-Almenta, Violeta
  • Calahorra, Jesús
  • Agudo-Lera, María
  • Sagarzazu, Amaia
  • Rodríguez-González, Carlos J.
  • Gallart-Aragón, Tania
  • Eich, Christina
  • Sánchez-Martín, Rosario M.
  • Granados-Principal, Sergio
Background Active targeting by surface-modified nanoplatforms enables a more precise and elevated accumulation of nanoparticles within the tumor, thereby enhancing drug delivery and efficacy for a successful cancer treatment. However, surface functionalization involves complex procedures that increase costs and timelines, presenting challenges for clinical implementation. Biomimetic nanoparticles (BNPs) have emerged as unique drug delivery platforms that overcome the limitations of actively targeted nanoparticles. Nevertheless, BNPs coated with unmodified cells show reduced functionalities such as specific tumor targeting, decreasing the therapeutic efficacy. Those challenges can be overcome by engineering non-patient-derived cells for BNP coating, but these are complex and cost-effective approaches that hinder their wider clinical application. Here we present an immune-driven strategy to improve nanotherapeutic delivery to tumors. Our unique perspective harnesses T-cell exhaustion and tumor immune evasion to develop a groundbreaking new class of BNPs crafted from exhausted T-cells (NExT) of triple-negative breast cancer (TNBC) patients by specific culture methods without sophisticated engineering. Methods NExT were generated by coating PLGA (poly(lactic-co-glycolic acid)) nanoparticles with TNBC-derived T-cells exhausted in vitro by acute activation. Physicochemical characterization of NExT was made by dynamic light scattering, electrophoretic light scattering and transmission electron microscopy, and preservation and orientation of immune checkpoint receptors by flow cytometry. The efficacy of chemotherapy-loaded NExT was assessed in TNBC cell lines in vitro. In vivo toxicity was made in CD1 mice. Biodistribution and therapeutic activity of NExT were determined in cell-line- and autologous patient-derived xenografts in immunodeficient mice. Results We report a cost-effective approach with a good performance that provides NExT naturally endowed with immune checkpoint receptors (PD1, LAG3, TIM3), augmenting specific tumor targeting by engaging cognate ligands, enhancing the therapeutic efficacy of chemotherapy, and disrupting the PD1/PDL1 axis in an immunotherapy-like way. Autologous patient-derived NExT revealed exceptional intratumor accumulation, heightened chemotherapeutic index and efficiency, and targeted the tumor stroma in a PDL1+ patient-derived xenograft model of triple-negative breast cancer. Conclusions These advantages underline the potential of autologous patient-derived NExT to revolutionize tailored adoptive cancer nanotherapy and chemoimmunotherapy, which endorses their widespread clinical application of autologous patient-derived NExT., This work was funded by Instituto de Salud Carlos III (grants PI19/01533, CP19/00029 to S.G.-P.), Consejería de Economía, Conocimiento, Empresas y Universidad, Junta de Andalucía (grant P29/22/02 to S.G.-P.), by MCIN/AE (grant RTI2018.101309B-C22 and PID2022-140151OB-C22 funded by MCIN/AEI https://doi.org/10.13039/501100011033 and by the European Union NextGenerationEU/PRTR to J.A.M.), the Chair “Doctors Galera-Requena in cancer stem cell research” (CMC-CTS963 to J.A.M.), the European Regional Development Fund (European Union), Fundación Científica Asociación Española Contra el Cáncer, Junta Provincial de Jaén (AECC) (grant PRDJA19001BLAY to J.L.B.-C.,), Proyectos Intramurales ibs.GRANADA (grant INTRAIBS-2021-09 to C.G.-L.), Junta de Andalucía, Plan Andaluz de Investigación, Desarrollo e Innovación (grant POSTDOC_21_638 to C.G.-L.), Ministerio de Ciencia, Innovación y Universidades (grant FPU19/04450 to A.L.-T.), Junta de Andalucía, Consejería de Transformación Económica, Industria, Conocimiento y Universidades (grant DOC_01686 to J.C.)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Onychocolone A produced by the fungus Onychocola sp. targets cancer stem cells and stops pancreatic cancer progression by inhibiting MEK2-dependent cell signaling

  • Ramos, María C.
  • Crespo-Sueiro, Gloria
  • de Pedro, Nuria
  • Griñán-Lisón, Carmen
  • Díaz, Caridad
  • Pérez-Victoria, Ignacio
  • González-Menendez, Víctor
  • Castillo, Francisco
  • Pérez del Palacio, José
  • Tormo, José R.
  • Choquesillo-Lazarte, Duane
  • Marchal, Juan A.
  • Vicente, Francisca
  • Fernández-Godino, Rosario
  • Genilloud, Olga
  • Reyes, Fernando
Pancreatic cancer (PC) shows a high fatality rate that can only be faced with a combination of surgery and chemotherapy or palliative treatment in the case of advanced patients. Besides, PC tumors are enriched with subpopulations of cancer stem cells (CSCs) that are resistant to the existing chemotherapeutic agents, which raises an important need for the identification of new drugs. To fill this gap, we have tested the anti-tumoral activity of microbial extracts, which chemical diversity offers a broad spectrum of potential new bioactive compounds. Extracts derived from the fungus Onychocola sp. CF-107644 were assayed via high throughput screening followed by bioassay-guided fractionation and resulted in the identification and isolation of six benzophenone derivatives with antitumoral activity: onychocolones A-F (#1-6). The structures of the compounds were established by spectroscopic methods, including ESI-TOF MS, 1D and 2D NMR analyses and X-ray diffraction. Compounds #1-4 significantly inhibited the growth of the pancreas tumoral cell lines, with low-micromolar Median Effective Doses (EDs). Compound #1 (onychocolone A) was prioritized for further profiling due to its pro-apoptotic effect, which was further validated on 3D spheroids and pancreatic CSCs. Protein expression assays showed that the effect was mechanistically linked to the inhibition of MEK onco-signaling pathway. The efficacy of onychocolone A was also demonstrated in vivo by the reduction of tumor growth in a pancreatic xenograft mouse model generated by CSCs. Altogether, the data support that onychocolone A is a promising new small molecule for hit-to-lead development of a new treatment for PC., The HPLC, IR NMR equipment, and plate readers used in this work were purchased via grants for scientific and technological infrastructures from the Ministerio de Ciencia e Innovación of Spain (Grant numbers PCT-010000\u20132010\u20134, INP-2011\u20130016-PCT-010000 ACT6, INP-2011\u20130016-PCT-010000 ACT6, PCT-300000\u20132009\u20130016) and from the Ministerio de Ciencia e Innovación of Spain (grant PID2022-140151OB-C22 funded by MCIN/AEI 10.13039/501100011033 and by the European Union NextGenerationEU/PRTR) anf the Chair \u201CDoctors Galera-Requena in cancer stem cell research\u201D (CMC-CTS963)., Peer reviewed